Neoplasm Metastasis  >>  luminespib (AUY922)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luminespib (AUY922) / Ligand
NCT01484860: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

Terminated
2
15
Canada
AUY922
University Health Network, Toronto, Novartis Pharmaceuticals
Adenocarcinoma of the Pancreas, Metastatic Disease
08/13
08/13

Download Options